Resource Library
/
Utilization of High Sensitivity Proteomics NULISA HT Panels for Clinical Biomarker Profiling: Assay Qualification and Regulatory Consideration
poster
This first-ever reported study demonstrates the rigorous qualification of NULISAseq high-throughput (HT) panels for clinical biomarker profiling across multiple biomatrices—highlighting Frontage’s leadership in delivering high-sensitivity, multiplexed, and regulatory-ready biomarker assay solutions.
Register to gain access to gated resources.
"*" indicates required fields
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.
